Skip to content
Capmatinib & SC Daratumumab episode artwork

May 8, 2020 16 min

Capmatinib & SC Daratumumab

from OncoPharm Hosted by John Bossaer

First, we discuss the FDA approval of daratumumab hyaluronidase for subcutaneous administration and compare its administration to SC administration of rituximab hyaluronidase and trastuzumab hyaluronidase. We end by discussing the 1st FDA-approved drug for MET exon 14 skipping mutations, capmatinib. We also discuss how a receptor tyrosine kinase could skip.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Capmatinib & SC Daratumumab

0:00 16:17

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OncoPharm?

This episode is 16 minutes long.

When was this OncoPharm episode published?

This episode was published on May 8, 2020.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.